Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12.

Maguire JJ, Davenport AP.

Br J Pharmacol. 2014 Dec;171(24):5555-72. doi: 10.1111/bph.12874. Review.

2.

The endothelin axis: a novel target for pharmacotherapy of female malignancies.

Smollich M, Wülfing P.

Curr Vasc Pharmacol. 2007 Jul;5(3):239-48. Review.

PMID:
17627567
3.

Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.

Battistini B, Verreault M, Ayach B, Blouin A, Cernacek P, Jeng AY, Wessale J, Opgenorth T, Tsang J.

J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S386-9.

PMID:
15838327
4.

Endothelin.

Davenport AP, Maguire JJ.

Handb Exp Pharmacol. 2006;(176 Pt 1):295-329. Review.

PMID:
16999223
5.

Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.

Sidharta PN, Krähenbühl S, Dingemanse J.

Expert Opin Drug Metab Toxicol. 2015 Mar;11(3):437-49. doi: 10.1517/17425255.2015.1000859. Review.

PMID:
25604973
6.

Endothelin.

Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ.

Pharmacol Rev. 2016 Apr;68(2):357-418. doi: 10.1124/pr.115.011833. Review.

7.

Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.

Gatfield J, Mueller Grandjean C, Sasse T, Clozel M, Nayler O.

PLoS One. 2012;7(10):e47662. doi: 10.1371/journal.pone.0047662.

8.

Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways.

Maguire JJ, Kuc RE, Pell VR, Green A, Brown M, Kumar S, Wehrman T, Quinn E, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):544-9. doi: 10.1016/j.lfs.2012.03.021.

9.

Modulation of human colon tumor-stromal interactions by the endothelin system.

Egidy G, Juillerat-Jeanneret L, Jeannin JF, Korth P, Bosman FT, Pinet F.

Am J Pathol. 2000 Dec;157(6):1863-74.

10.

Endothelin receptor antagonists in pulmonary arterial hypertension.

Dupuis J, Hoeper MM.

Eur Respir J. 2008 Feb;31(2):407-15. doi: 10.1183/09031936.00078207. Review.

11.

The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.

Seed A, Kuc RE, Maguire JJ, Hillier C, Johnston F, Essers H, de Voogd HJ, McMurray J, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):743-8. doi: 10.1016/j.lfs.2012.03.022.

12.

The endothelin system in pulmonary arterial hypertension.

Galié N, Manes A, Branzi A.

Cardiovasc Res. 2004 Feb 1;61(2):227-37. Review.

PMID:
14736539
14.

Differential regulation of the lung endothelin system by urban particulate matter and ozone.

Thomson E, Kumarathasan P, Goegan P, Aubin RA, Vincent R.

Toxicol Sci. 2005 Nov;88(1):103-13.

PMID:
16081523
15.
16.

Endothelin receptor antagonists as disease modifiers in systemic sclerosis.

Shetty N, Derk CT.

Inflamm Allergy Drug Targets. 2011 Feb;10(1):19-26. Review.

PMID:
21184655
17.
18.
19.

Ontogeny of endothelins-1 and -3, their receptors, and endothelin converting enzyme-1 in the early human embryo.

Brand M, Le Moullec JM, Corvol P, Gasc JM.

J Clin Invest. 1998 Feb 1;101(3):549-59.

20.

Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of the endothelin system.

Yamamoto K, Masuyama T, Sakata Y, Doi R, Ono K, Mano T, Kondo H, Kuzuya T, Miwa T, Hori M.

Cardiovasc Res. 2000 Jun;46(3):421-32.

PMID:
10912453
Items per page

Supplemental Content

Support Center